Open Payments

SANA LOUISE JOHNSON-QUIJADA

Type
Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
Where
TEMECULA, CA
NPI
1194882860
Received
$186,935 in 959 records, 2019 to 2025 ($185,650 general, $1,284 research)
As principal investigator
$2,359,506 of research payments to others in 353 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment69$14,703
2024General payment65$11,219
2023General payment170$67,218
2022General payment112$37,043
2021General payment197$21,359
2020General payment137$17,037
2019General payment203$17,068
2019Research payment6$1,284

By company

CompanyRecordsAmountYears
IDORSIA PHARMACEUTICALS US INC121$65,8662022–2024
ABBVIE INC.151$49,5622021–2025
Otsuka America Pharmaceutical, Inc.191$42,6232019–2025
Allergan, Inc.124$23,2622019–2021
Otsuka Pharmaceutical Development & Commercialization, Inc.8$1,3232019–2022
Lundbeck LLC129$1,0172019–2025
Takeda Pharmaceuticals U.S.A., Inc.82$6082019–2022
Vanda Pharmaceuticals Inc.24$4082019–2025
Sunovion Pharmaceuticals Inc.25$3692019–2022
Bausch Health US, LLC21$3682022–2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)16$3352022–2025
Teva Pharmaceuticals USA, Inc.8$2822023–2024
Janssen Pharmaceuticals, Inc16$2802019–2025
Neurocrine BioSciences, Inc.12$2432022–2025
Eisai Inc.21$1962020–2021
Axsome Therapeutics, Inc.6$1102022–2024
Novo Nordisk Inc1$302025
Alkermes, Inc.1$222019
Merck Sharp & Dohme LLC1$122022
Neuronetics, Inc.1$92025

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v100$153,620
Travel and Lodging91$20,959
Food and Beverage758$10,942
Research payment6$1,284
Education4$128

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-16Lundbeck LLC$25Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-12-16ABBVIE INC.$8Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-12-15ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$17Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-12-02Otsuka America Pharmaceutical, Inc.$12Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-11-24ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$9Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-11-22Novo Nordisk Inc$30Food and BeverageIn-kind items and servicesWegovy Drug, Obesity2025
2025-10-31ABBVIE INC.$13Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-10-20ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$33Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-10-18Lundbeck LLC$10Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-10-14Otsuka America Pharmaceutical, Inc.$26Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-10-13Otsuka America Pharmaceutical, Inc.$10Food and BeverageIn-kind items and servicesABILIFY MAINTENA Drug, PSYCHIATRY2025
2025-10-13Otsuka America Pharmaceutical, Inc.$0Food and BeverageIn-kind items and servicesABILIFY MAINTENA Drug, PSYCHIATRY2025
2025-10-09ABBVIE INC.$5Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-10-08Otsuka America Pharmaceutical, Inc.$2,106Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-10-08ABBVIE INC.$9Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-09-30ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$25Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-09-26ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$18Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-09-23Lundbeck LLC$26Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-09-17Vanda Pharmaceuticals Inc.$37Food and BeverageIn-kind items and servicesFANAPT Drug, SCHIZOPHRENIA2025
2025-09-11Bausch Health US, LLC$24Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2025
2025-09-09ABBVIE INC.$12Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-09-08Neurocrine BioSciences, Inc.$16Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-09-08Lundbeck LLC$9Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-09-08Lundbeck LLC$2Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-08-28Janssen Pharmaceuticals, Inc$42Food and BeverageIn-kind items and servicesSPRAVATO Drug, Neuroscience2025
2025-08-26ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2025
2025-08-26ABBVIE INC.$90Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-08-26ABBVIE INC.$18Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-08-22Otsuka America Pharmaceutical, Inc.$2,106Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-08-19Otsuka America Pharmaceutical, Inc.$21Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-08-06Otsuka America Pharmaceutical, Inc.$18Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-08-04Lundbeck LLC$17Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-07-31ABBVIE INC.$29Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-07-10Bausch Health US, LLC$24Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2025
2025-06-26ABBVIE INC.$8Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-06-17Otsuka America Pharmaceutical, Inc.$27Food and BeverageIn-kind items and servicesABILIFY ASIMTUFII Drug, PSYCHIATRY2025
2025-06-16ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$16Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-06-10Neurocrine BioSciences, Inc.$14Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-05-20Otsuka America Pharmaceutical, Inc.$17Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-05-20Otsuka America Pharmaceutical, Inc.$2Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-05-13Lundbeck LLC$30Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-05-05Bausch Health US, LLC$21Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2025
2025-04-28Lundbeck LLC$12Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-04-23Janssen Pharmaceuticals, Inc$20Food and BeverageIn-kind items and servicesSPRAVATO Drug, Neuroscience2025
2025-04-23ABBVIE INC.$6Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-04-18Otsuka America Pharmaceutical, Inc.$351Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-04-17ABBVIE INC.$6Food and BeverageIn-kind items and servicesVIIBRYD Drug, NEUROSCIENCE2025
2025-04-11Neurocrine BioSciences, Inc.$17Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-04-07Vanda Pharmaceuticals Inc.$16Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2025
2025-03-19Vanda Pharmaceuticals Inc.$20Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2025
2025-02-26Vanda Pharmaceuticals Inc.$19Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2025
2025-02-22Lundbeck LLC$19Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-02-21ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2025
2025-02-21ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2025
2025-02-19Bausch Health US, LLC$15Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2025
2025-02-19ABBVIE INC.$15Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-02-19Otsuka America Pharmaceutical, Inc.$6Food and BeverageIn-kind items and servicesABILIFY ASIMTUFII Drug, PSYCHIATRY2025
2025-02-11ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2025
2025-02-11Neurocrine BioSciences, Inc.$16Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-02-05ABBVIE INC.$26Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-01-29ABBVIE INC.$23Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-01-24Lundbeck LLC$9Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2025
2025-01-23ABBVIE INC.$19Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-01-22ABBVIE INC.$5Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-01-21Otsuka America Pharmaceutical, Inc.$15Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2025
2025-01-16ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$33Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2025
2025-01-14ABBVIE INC.$6Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2025-01-11Neuronetics, Inc.$9Food and BeverageCash or cash equivalentNEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM2025
2025-01-07ABBVIE INC.$7Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2025
2024-12-21Lundbeck LLC$28Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-12-16Bausch Health US, LLC$18Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-12-12ABBVIE INC.$23Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-12-03ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$19Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2024
2024-11-26Otsuka America Pharmaceutical, Inc.$7Food and BeverageIn-kind items and servicesABILIFY ASIMTUFII Drug, PSYCHIATRY2024
2024-11-25Bausch Health US, LLC$8Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-11-19ABBVIE INC.$6Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-11-18ABBVIE INC.$14Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-11-13Otsuka America Pharmaceutical, Inc.$24Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-11-12ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$15Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2024
2024-11-06Lundbeck LLC$20Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-09-23Otsuka America Pharmaceutical, Inc.$8Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-09-03ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$15Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2024
2024-08-20IDORSIA PHARMACEUTICALS US INC$21Food and BeverageIn-kind items and servicesQUVIVIQ Drug, Insomnia2024
2024-08-07Otsuka America Pharmaceutical, Inc.$789Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-08-07Janssen Pharmaceuticals, Inc$25Food and BeverageIn-kind items and servicesSPRAVATO Drug, Neuroscience2024
2024-08-07Bausch Health US, LLC$24Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-08-06Otsuka America Pharmaceutical, Inc.$10Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-07-30ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2024
2024-07-30Vanda Pharmaceuticals Inc.$20Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2024
2024-07-15ABBVIE INC.$25Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-07-15Vanda Pharmaceuticals Inc.$17Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2024
2024-07-10Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-07-09ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2024
2024-07-09Neurocrine BioSciences, Inc.$18Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-06-20ABBVIE INC.$19Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-06-10Janssen Pharmaceuticals, Inc$17Food and BeverageIn-kind items and servicesINVEGA SUSTENNA Drug, Neuroscience2024
2024-05-28Janssen Pharmaceuticals, Inc$15Food and BeverageIn-kind items and servicesSPRAVATO Drug, Neuroscience2024
2024-05-22ABBVIE INC.$19Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-05-16Lundbeck LLC$15Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-05-15Otsuka America Pharmaceutical, Inc.$2,106Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-05-14ABBVIE INC.$24Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-05-03Otsuka America Pharmaceutical, Inc.$351Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-05-02Teva Pharmaceuticals USA, Inc.$30Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-05-01Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-04-30Vanda Pharmaceuticals Inc.$24Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2024
2024-04-29ABBVIE INC.$17Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-04-24Otsuka America Pharmaceutical, Inc.$29Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-04-23Otsuka America Pharmaceutical, Inc.$25Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-04-18ABBVIE INC.$13Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-04-16Otsuka America Pharmaceutical, Inc.$21Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-04-12Lundbeck LLC$17Food and BeverageCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-04-10Bausch Health US, LLC$17Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-04-09ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$13Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2024
2024-03-28Neurocrine BioSciences, Inc.$33Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-03-27Bausch Health US, LLC$11Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-03-15Otsuka America Pharmaceutical, Inc.$175Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2024
2024-03-14Otsuka America Pharmaceutical, Inc.$11Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-02-29ABBVIE INC.$12Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-02-28Bausch Health US, LLC$20Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-02-22Teva Pharmaceuticals USA, Inc.$25Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-02-21ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2024
2024-02-13Otsuka America Pharmaceutical, Inc.$21Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2024-02-08ABBVIE INC.$3Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-02-07Bausch Health US, LLC$16Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-01-31ABBVIE INC.$28Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-01-31ABBVIE INC.$7Travel and LodgingIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-01-31ABBVIE INC.$6Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-01-30ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$24Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2024
2024-01-25Axsome Therapeutics, Inc.$16Food and BeverageIn-kind items and servicesSunosi Drug, Neurology2024
2024-01-23Bausch Health US, LLC$1EducationIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-01-18Neurocrine BioSciences, Inc.$16Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2024
2024-01-17Bausch Health US, LLC$19Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2024
2024-01-09ABBVIE INC.$18Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2024-01-04Otsuka America Pharmaceutical, Inc.$21Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2024
2023-12-12ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2023
2023-12-12ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2023
2023-12-07Neurocrine BioSciences, Inc.$19Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2023
2023-12-07IDORSIA PHARMACEUTICALS US INC$6Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-12-05Janssen Pharmaceuticals, Inc$31Food and BeverageIn-kind items and servicesSPRAVATO Drug, Neuroscience2023
2023-12-05Otsuka America Pharmaceutical, Inc.$17Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-11-30Vanda Pharmaceuticals Inc.$24Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2023
2023-11-21ABBVIE INC.$49Travel and LodgingIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-11-21ABBVIE INC.$16Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-11-21ABBVIE INC.$15Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-11-21ABBVIE INC.$15Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-11-20ABBVIE INC.$20Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-11-20ABBVIE INC.$20Travel and LodgingIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-11-20Bausch Health US, LLC$15Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2023
2023-11-16Teva Pharmaceuticals USA, Inc.$30Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2023
2023-11-13ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$14Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2023
2023-11-09Otsuka America Pharmaceutical, Inc.$29Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-11-02IDORSIA PHARMACEUTICALS US INC$7Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-10-30Otsuka America Pharmaceutical, Inc.$19Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-10-26Axsome Therapeutics, Inc.$28Food and BeverageIn-kind items and servicesSunosi Drug, Neurology2023
2023-10-16Otsuka America Pharmaceutical, Inc.$24Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-10-12ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$14Food and BeverageIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2023
2023-10-11Bausch Health US, LLC$22Food and BeverageIn-kind items and servicesAPLENZIN Drug, Neurology2023
2023-10-10Teva Pharmaceuticals USA, Inc.$76EducationIn-kind items and services2023
2023-10-10Teva Pharmaceuticals USA, Inc.$27Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2023
2023-10-05ABBVIE INC.$24Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-10-05IDORSIA PHARMACEUTICALS US INC$4Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-09-18Vanda Pharmaceuticals Inc.$19Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2023
2023-09-15IDORSIA PHARMACEUTICALS US INC$2,632Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-09-15IDORSIA PHARMACEUTICALS US INC$125Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-09-14Otsuka America Pharmaceutical, Inc.$19Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-09-13Otsuka America Pharmaceutical, Inc.$72Travel and LodgingCash or cash equivalentREXULTI Drug, PSYCHIATRY2023
2023-09-13Otsuka America Pharmaceutical, Inc.$70Travel and LodgingCash or cash equivalentREXULTI Drug, PSYCHIATRY2023
2023-09-07Neurocrine BioSciences, Inc.$34Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2023
2023-09-07Otsuka America Pharmaceutical, Inc.$21Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-09-06Otsuka America Pharmaceutical, Inc.$2,106Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2023
2023-09-06IDORSIA PHARMACEUTICALS US INC$1,063Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-08-31IDORSIA PHARMACEUTICALS US INC$124Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-08-31Otsuka America Pharmaceutical, Inc.$29Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-08-31IDORSIA PHARMACEUTICALS US INC$6Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-08-29ABBVIE INC.$14Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-08-29Vanda Pharmaceuticals Inc.$14Food and BeverageIn-kind items and servicesHETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER2023
2023-08-25IDORSIA PHARMACEUTICALS US INC$400Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-08-25IDORSIA PHARMACEUTICALS US INC$286Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-08-25IDORSIA PHARMACEUTICALS US INC$278Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-08-25IDORSIA PHARMACEUTICALS US INC$19Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-08-24Axsome Therapeutics, Inc.$15Food and BeverageIn-kind items and servicesSunosi Drug, Neurology2023
2023-08-17IDORSIA PHARMACEUTICALS US INC$12Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-08-03ABBVIE INC.$21Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-07-28IDORSIA PHARMACEUTICALS US INC$2,632Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-07-25ABBVIE INC.$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVRAYLAR Drug, NEUROSCIENCE2023
2023-07-22IDORSIA PHARMACEUTICALS US INC$125Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023
2023-07-17Otsuka America Pharmaceutical, Inc.$22Food and BeverageIn-kind items and servicesABILIFY ASIMTUFII Drug, PSYCHIATRY2023
2023-07-17Axsome Therapeutics, Inc.$21Food and BeverageIn-kind items and servicesSunosi Drug, Neurology2023
2023-07-13IDORSIA PHARMACEUTICALS US INC$151Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-07-13Otsuka America Pharmaceutical, Inc.$23Food and BeverageIn-kind items and servicesREXULTI Drug, PSYCHIATRY2023
2023-07-12Otsuka America Pharmaceutical, Inc.$1,140Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREXULTI Drug, PSYCHIATRY2023
2023-07-10ABBVIE INC.$28Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-07-10ABBVIE INC.$27Travel and LodgingIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2023
2023-07-06Teva Pharmaceuticals USA, Inc.$24Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2023
2023-06-30IDORSIA PHARMACEUTICALS US INC$2,835Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-06-30IDORSIA PHARMACEUTICALS US INC$124Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-06-30IDORSIA PHARMACEUTICALS US INC$124Travel and LodgingCash or cash equivalentQUVIVIQ Drug, INSOMNIA2023
2023-06-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$48EducationIn-kind items and servicesCAPLYTA Drug, PSYCHIATRY2023
2023-06-29Neurocrine BioSciences, Inc.$13Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2023
2023-06-29IDORSIA PHARMACEUTICALS US INC$8Food and BeverageIn-kind items and servicesQUVIVIQ Drug, INSOMNIA2023

The latest 200 records of 959.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-01-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$5,476AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2025
2024-07-17Boehringer Ingelheim Pharmaceuticals, Inc.VIKING CLINICAL RESEARCH$4,573Proof of concept and DRF in BPD2024
2024-05-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$9,035A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2024
2024-03-21Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$1,080A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN2024
2023-10-04ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$2,997AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-08-30ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$2,128AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-08-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,034AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-08-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$5,335A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-08-01Boehringer Ingelheim Pharmaceuticals, Inc.VIKING CLINICAL RESEARCH$400Proof of concept and DRF in BPD2023
2023-07-06ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$2,128AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-07-06ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$5,553A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-06-03ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$2,537A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-06-03ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$2,561AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-05-03ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$3,333AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-03-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$3,469AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-03-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,613A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-03-23Sage Therapeutics, LLCVIKING CLINICAL RESEARCH$13,806A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjec2023
2023-03-16Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$89A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132023
2023-03-16Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$393A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132023
2023-03-16Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$782A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132023
2023-03-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$2,829AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-03-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,386A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-02-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$3,000A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-02-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$863AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2023
2023-02-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$3,704A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2023
2023-02-01Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$8,940A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132023
2023-01-01Boehringer Ingelheim International GmbHVIKING CLINICAL RESEARCH$166Proof of concept and DRF in BPD2023
2022-12-29Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$9,726A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132022
2022-12-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,755AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2022
2022-12-22Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$1,075A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2022
2022-12-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$553AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2022
2022-12-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$8,129A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-11-03ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$5,982A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-09-02Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$4,662A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132022
2022-08-25Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$7,522A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN2022
2022-08-05Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$4,406A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132022
2022-06-29Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$28,264A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132022
2022-06-07ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,250A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-05-26Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$1,100A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WI2022
2022-05-19Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,514A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2022
2022-05-06ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,748AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2022
2022-05-05Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$16,246A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2022
2022-04-28Boehringer Ingelheim Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$21,407Proof of concept and DRF in BPD2022
2022-04-07Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$398A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2022
2022-03-28Boehringer Ingelheim Pharmaceuticals, Inc.VIKING CLINICAL RESEARCH$924Proof of concept and DRF in BPD2022
2022-03-25ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$1,920A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-03-17Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,364A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2022
2022-03-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$8,131AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2022
2022-03-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$20,526A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-02-22ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$5,000A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-02-17Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$500A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2022
2022-02-03Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$3,728A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2022
2022-02-03Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$68,723A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN2022
2022-02-02Supernus Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$7,950A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5132022
2022-02-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,500AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2022
2022-02-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$15,271A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2022
2022-01-27Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$5,019A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2022
2022-01-27Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$9,596A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY OF SAGE-217 IN THE TR2022
2022-01-20Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$9,475A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2022
2022-01-20Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$13,559A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTI2022
2022-01-04Boehringer Ingelheim Pharmaceuticals, Inc.VIKING PHARMACEUTICAL TRIALS INC$91,123Proof of concept and DRF in MDD2022
2022-01-01Boehringer Ingelheim International GmbHVIKING CLINICAL RESEARCH$499Proof of concept and DRF in BPD2022
2022-01-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$2,995Proof of concept and DRF in MDD2022
2022-01-01Boehringer Ingelheim International GmbHVIKING CLINICAL RESEARCH$499Proof of concept and DRF in BPD2022
2021-12-31Allergan, Inc.VIKING CLINICAL RESEARCH LTD$714A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-12-31Boehringer Ingelheim International GmbHVIKING CLINICAL RESEARCH$249Proof of concept and DRF in BPD2021
2021-12-28ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$4,617A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU2021
2021-12-16Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$2,751A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2021
2021-12-16Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$2Proof of concept and DRF in MDD2021
2021-12-14Allergan, Inc.VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA$17,241A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-12-09Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,489A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2021
2021-12-03Allergan, Inc.VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA$750A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-12-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$1,700A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU2021
2021-12-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$49Proof of concept and DRF in MDD2021
2021-11-18Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,000A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD)2021
2021-11-10Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,786A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-11-10Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$2,269A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-11-10Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$16,257A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2021
2021-11-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$50Proof of concept and DRF in MDD2021
2021-10-21Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$10,066A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2021
2021-10-21Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$2,338A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-10-21Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,270A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-10-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$50Proof of concept and DRF in MDD2021
2021-09-23Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$5,283A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2021
2021-09-23Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$8,897A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-09-14Allergan, Inc.VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA$5,263A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-09-09Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$500A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY OF SAGE-217 IN THE TR2021
2021-09-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)VIKING PHARMACEUTICAL TRIALS INC$7,500A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU2021
2021-09-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$51Proof of concept and DRF in MDD2021
2021-08-26Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$330Proof of concept and DRF in MDD2021
2021-08-13Allergan, Inc.VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA$9,095A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-08-12Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$9,381A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER2021
2021-08-12Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$1,442A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-08-09Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$80Proof of concept and DRF in MDD2021
2021-08-05Otsuka Pharmaceutical Development & Commercialization, Inc.VIKING PHARMACEUTICAL TRIALS INC$29,348A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTI2021
2021-08-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$42Proof of concept and DRF in MDD2021
2021-08-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$26Proof of concept and DRF in MDD2021
2021-08-01Boehringer Ingelheim Pharma GmbH & Co.KGVIKING CLINICAL RESEARCH$52Proof of concept and DRF in MDD2021
2021-07-15Sage Therapeutics, LLCVIKING PHARMACEUTICAL TRIALS INC$169A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-07-13Allergan, Inc.VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA$22,008A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Riverside CountyTemecula city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Temecula, CA, county Riverside County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Temecula, CA
County
Riverside County, CA
State
California
Population B01003111,1672,478,60039,287,377
Population, 2020 census P1110,0032,418,18539,538,223
Median age B0100236.737.037.9
Under 18 B0100126.8%24.1%22.0%
65 and over B0100112.7%15.4%15.7%
Households B1100136,536775,33513,548,091
Foreign born B0500215.9%21.9%27.0%
Median household income B19013$121,063$93,074$99,122
Median family income B19113$130,015$103,984$113,346
Per capita income B19301$47,086$38,317$49,513
Poverty rate B170017.3%10.6%12.0%
Unemployment rate B230255.7%6.5%6.6%
Civilian labor force B2302555,4971,191,32320,068,466
Mean commute (minutes) B0801336.333.828.7
Bachelor's degree or higher B1500338.8%25.6%37.1%
Housing units B2500137,813869,41414,644,735
Owner-occupied B2500368.0%69.1%55.9%
Renters B2500332.0%30.9%44.1%
Median home value B25077$679,700$557,300$734,700
Median gross rent B25064$2,347$1,901$2,036
White, not Hispanic B0300248.4%31.0%33.8%
Black B030024.7%6.0%5.2%
Hispanic or Latino B0300229.0%51.3%40.2%
Asian B0300210.3%6.9%15.3%
American Indian and Alaska Native B030020.2%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Temecula, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.